Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.73 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.65 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | HAT1 | O14929 | 2/20 | 0.46 |
| ▸ | EP300 | Q09472 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2036909 | 0.84 | NR4A2 (1.00) | NR4A2BRPF1CNR2POLBRAB9A | |
| SCHEMBL6029970 | 0.84 | NR4A2 (0.51) | NR4A2BRPF1CNR2ALDH1A1HPGD | |
| SCHEMBL6029339 | 0.84 | ALDH1A1 (0.62) | NR4A2BRPF1CNR2POLBRAB9A | |
| SCHEMBL14486971 | 0.84 | NR4A2 (0.62) | NR4A2BRPF1RAB9AALDH1A1HPGD | |
| SCHEMBL7210602 | 0.84 | NR4A2 (0.51) | NR4A2BRPF1RAB9A | |
| SCHEMBL3720911 | 0.81 | BRPF1 (0.69) | NR4A2BRPF1CNR2POLBRAB9A | |
| SCHEMBL3978031 | 0.80 | BRPF1 (0.77) | NR4A2BRPF1CNR2POLBRAB9A | |
| SCHEMBL6329279 | 0.80 | NR4A2 (0.48) | NR4A2BRPF1POLBALDH1A1HPGD | |
| SCHEMBL6029923 | 0.79 | ALDH1A1 (0.49) | NR4A2BRPF1RAB9AALDH1A1HPGD | |
| SCHEMBL6329709 | 0.79 | NR4A2 (0.47) | NR4A2BRPF1RAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2246346-B1 | Indolylmaleimide derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-1490355-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| EP-1904482-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2270001-A1 | Indolylmaleimide derivatives as PKC inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2007006533-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050119274-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1490355-A1 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082859-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032507-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | NR4A2 4254/4885BRPF1 4133/4885CNR2 2583/4885 |
| US-20050119274-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | NR4A2 4254/4885BRPF1 4133/4885CNR2 2583/4885 |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | RB1, INMT, IDH3A | NR4A2 2887/4885BRPF1 1588/4885CNR2 298/4885 |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | DGKK, DGKG, HLA-DRB1 | NR4A2 3810/4885BRPF1 4251/4885CNR2 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.